MAPT and tauopathy: In a future study, we aim to use our peptidomic approach to verify the identified tau proteolytic peptides and brain protein-breakdown products in tauopathy neurodegenerative disease models (e.g., TBI and CTE) and human tauopathy bio-fluid samples (e.g., blood, serum, and cerebrospinal fluid (CSF)).